![]() ![]() ![]() The video recording is available of EMA's latest COVID-19 and other public health emergencies press briefingĮMA is holding a regular press briefing on COVID-19 and other public health emergencies on Wednesday 15 February 2023ĮMA published the assessment report for Spikevax supporting the extension of indication for use of its adapted BA.1 version as a booster in children aged 6 to 11 The European Commission authorised Bimervax (previously COVID-19 Vaccine HIPRA)ĮMA's CHMP recommended authorising Bimervax (previously COVID-19 Vaccine HIPRA) as a booster in people aged 16 years and olderĮMA recommends approval of Bimervax as a COVID-19 booster vaccineĮMA's CHMP started evaluating the marketing authorisation application for Bimervax (previously COVID-19 Vaccine HIPRA)ĮMA published clinical data for Spikevax supporting the use of its adapted BA.1 version as a booster in children aged 6 to 11ĮMA's CHMP recommended authorising COVID-19 Vaccine Valneva as a booster in adults aged 18 to 50ĬOVID-19 Vaccine (inactivated, adjuvanted) ValnevaĮMA published clinical data supporting the use of Vaxzevria as a booster doseĮMA's CHMP approved a new manufacturing site for the active substance of NuvaxovidĮMA published updated information for COVID-19 Vaccine Valneva, with an increase in its approved shelf life ![]() Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24 - 26 April 2023ĮMA's CHMP recommended an extension of indication for Ronapreve to include people aged 12 and older with a negative antibody test who are receiving Oxygen The video recording is available of EMA's last regular COVID-19 and other public health emergencies press briefingĮMA regular press briefing on public health emergenciesĮMA is holding its last regular press briefing on COVID-19 and other public health emergencies on Tuesday 6 June 2023ĮMA's CHMP recommended converting the conditional marketing for Nuvaxovid to standard marketing authorisationĮMA's CHMP recommended extending the shelf life of Nuvaxovid from 9 to 12 monthsĮMA published clinical data for COVID-19 Vaccine Valneva supporting its use as a booster in adults aged 18 to 50ĮMA published clinical data for Evusheld supporting its use to treat COVID-19 in adults and adolescentsĮMA published clinical data for Evusheld supporting its use to prevent COVID-19 in adults and adolescentsĮMA published clinical data for VidPrevtyn Beta supporting its use as a vaccine in adultsĮMA's CHMP recomended an extension of indication for Spikevax to include use of its adapted BA.4-5 version as a booster in children aged 6 to 11 ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |